Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT04680975 is registered in ClinicalTrials.gov with Kadmon, a Sanofi Company as lead sponsor.

NCT NCT04680975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Lead sponsor
Kadmon, a Sanofi Company
Phase
Phase 2
Overall status
Terminated
Start date
March 3, 2021
Completion date
December 19, 2022
Enrollment
10 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis